Insiders Trades
AnGes, Inc.: what insiders have been doing
Every trade that managers of AnGes, Inc. disclose to EDINET (Japan FSA) is tracked on this page. The company sits in the Health Care sector. Between 18 October 2025 and 18 October 2026, 2 insiders published 5 filings.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Insider buying of AnGes, Inc. has been absent for the past year. Between a trade and the moment it shows up on EDINET (Japan FSA), the median delay is 4 days. Until a filing is published, the market cannot know about the trade.
Compared with its exchange (3,427 companies, median 3 filings), a count of 5 filings is above the norm.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. Every figure here comes from the filings published by EDINET (Japan FSA) and describes the past, not future prices; it is not investment advice.
Insider Decl.
42
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 22,849 of 24,148 companies
16.3
score / 100
Value5
Quality28
FCF yld-47%
Earn yld-41%
EV/EBITDA·
ROE-215%
Gross mgn37%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
JP¥33
Analyst consensus
Income statement
RevenueJP¥874.1M
Gross profitJP¥320.4M37% margin
EBITDA-JP¥5.1B-582% margin
Net income-JP¥5.1B-586.1% margin
Valuation
P/Book64.2x
Beta0.57
Balance sheet & cash
Market capJP¥13.2B
Total debtJP¥54.4M
Free Cash Flow-JP¥5.8B
Debt / Equity352%
Profitability & ownership
ROE-214.6%
ROA-79.1%
% insiders8.1%
% institutions3.0%
Last declaration on 29 September 2026
Declarations42 total
49.0% of flowShareXTKSEDINET:S100Z4TI
ShareXTKSEDINET:S100Z3ND
100.0% of flowShareXTKSEDINET:S100Z0NF
0.8% of flowShareXTKSEDINET:S100XF2G
0.8% of flowShareXTKSEDINET:S100X7SU
32.6% of flowShareXTKSEDINET:S100WLRX
67.4% of flowShareXTKSEDINET:S100WK0C
ShareXTKSEDINET:S100WJK5
0.3% of flowShareXTKSEDINET:S100WDVR
0.3% of flowShareXTKSEDINET:S100WA6O
0.4% of flowShareXTKSEDINET:S100VV37
0.5% of flowShareXTKSEDINET:S100VTGP
0.5% of flowShareXTKSEDINET:S100VMZU
0.6% of flowShareXTKSEDINET:S100VG4F
0.6% of flowShareXTKSEDINET:S100VDMJ
0.7% of flowShareXTKSEDINET:S100VC7Q
0.8% of flowShareXTKSEDINET:S100V8LU
0.8% of flowShareXTKSEDINET:S100V713
1.1% of flowShareXTKSEDINET:S100UX07
1.2% of flowShareXTKSEDINET:S100UM3E
1.3% of flowShareXTKSEDINET:S100ULVH
1.3% of flowShareXTKSEDINET:S100UJEJ
1.4% of flowShareXTKSEDINET:S100UHFP
0.3% of flowShareXTKSEDINET:S100TZNB
0.3% of flowShareXTKSEDINET:S100TPF9
25 of 42 declarations
About AnGes, Inc.
AnGes, Inc. is a company focused on the health and pharmaceutical sector, specializing in the development of gene therapies and vaccines. It is listed on the XTKS market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations